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Abstract The distal convoluted tubule (DCT) is the shortest
segment of the nephron and consists of an early (DCT1) and
late part (DCT2). Here, several transport proteins, like the
thiazide-sensitive NaCl cotransporter (NCC) and the epithe-
lial magnesium (Mg2+) channel (TRPM6), are exclusively
expressed. This makes the DCT the major site of active
transcellular Mg2+ reabsorption determining the final
excretion in the urine. Following the Mg2+ influx via the
apically localized TRPM6, intracellular Mg2+ diffuses to
the basolateral membrane where it is extruded to the blood
compartment via still-unidentified Mg2+ transporters. Recent
years have witnessed multiple breakthroughs in the field of
transcellular Mg2+ reabsorption. Epidermal growth factor
and estrogen were identified as magnesiotropic hormones by
their effect on TRPM6 activity. Intracellularly, receptor of
activated protein kinase C 1 and adenosine triphosphate
were shown to inhibit TRPM6 activity through its α-kinase
domain. Furthermore, dysregulation or malfunction of trans-
cellular Mg2+ reabsorption in DCT has been associated with
renal Mg2+ wasting. Mutations in TRPM6 are responsible for
hypomagnesemia with secondary hypocalcemia. A defect in
the γ-subunit of the Na+/K+-adenosine triphosphatase causes
isolated dominant hypomagnesemia resulting from renal
Mg2+ wasting. Moreover, in Gitelman’s syndrome, mutations
in NCC also result in impaired transcellular Mg2+ reabsorp-
tion in DCT. This review highlights our recently obtained
knowledge concerning the molecular regulation of trans-
cellular Mg2+ reabsorption.
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Introduction
The distal convoluted tubule
The renal distal tubule comprises anatomically discrete
segments (Fig. 1), including the thick ascending limb of
Henle (TAL) and the distal convoluted tubule (DCT), and
ends in the connecting tubule (CNT) [65]. In rodents and
humans, but not in rabbit, the segment of DCT can be
further subdivided into an early (DCT1) and late (DCT2)
portion [29–31]. The DCT plays an important role in fine-
tuning renal excretion of sodium (Na+), calcium (Ca2+), and
magnesium (Mg2+). Consequently, several transport pro-
teins for these cations are specifically present in this
nephron segment and are, therefore, frequently used as
markers for DCT cells (Table 1). First of all, a thiazide-
sensitive NaCl cotransporter (NCC) is a well-recognized
marker for DCT [40]. NCC is the major apical Na+
transporter in this nephron segment. Its expression begins
abruptly at the junction between TAL and DCT and ends at
the junction between DCT and CNT [3]. Moreover, along
the DCT, the abundance of NCC protein is high in the
DCT1 cells and gradually decreases in the DCT2 cells [30,
31, 66]. Another apical transporter, the amiloride-sensitive
epithelial Na+ channel (ENaC), is also present in DCT2 but
to a much lesser extent. ENaC is predominantly expressed
in CNT and cortical collecting duct (CCD) [31]. On the
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other hand, the Na+/K+-adenosine triphosphatase (ATPase)
is consistently present at the basolateral membrane of the
DCT. In addition, DCT1 is the major site of transcellular
Mg2+ reabsorption. This notion is supported by the fact that
the epithelial Mg2+ channel (TRPM6) is predominantly
expressed in DCT1 with a lower abundance in DCT2 [66].
Furthermore, TRPM6 co-localizes with parvalbumin in
DCT1 and with calbindin-D28K (CaBP28) in DCT2 [66].
Both parvalbumin and CaBP28 are cytoplasmic binding
proteins for Ca2+ and Mg2+ with distinct distribution patterns.
Fig. 1 Model of transcellular Mg2+ reabsorption. The renal distal
tubule in the nephron comprises anatomically discrete segments,
including the thick ascending limb of the loop of Henle (TAL) and the
distal convoluted tubule (DCT) that ends in the connecting tubule
(CNT). DCT plays an important role in fine-tuning renal excretion of
Mg2+. The epithelial Mg2+ channel (TRPM6) is predominantly
expressed in DCT1 with a lower abundance in DCT2. TRPM6 co-
localizes with NCC and parvalbumin in DCT1 and with calbindin-
D28K in DCT2. Mg
2+ influx via TRPM6 is controlled by the luminal
and intracellular free Mg2+. Another intracellular TRPM6-associated
protein is RACK1, which can inhibit TRPM6 activity by binding to its
α-kinase domain. After Mg2+ influx via TRPM6, intracellular Mg2+
may be buffered and transported by a putative Mg2+-binding protein
(MgBP). The basolateral membrane harbors epidermal growth factor
receptor (EGFR), Na+/K+-ATPase, and possibly a Na+/Mg2+ exchang-
er and Mg2+-ATPase. The molecular identities of Na+/Mg2+ exchanger
and Mg2+-ATPase are still elusive. EGFR activation by EGF can
enhance Mg2+ influx by increasing TRPM6 membrane expression.
FXYD2 may bind as γ-subunit with α- and β-subunit of Na+/K+-
ATPase. A detailed mechanism by which FXYD2 regulates trans-
cellular Mg2+ reabsorption is still under investigation
Table 1 Distribution of transporters in DCT segment of the nephron
TAL DCT1 DCT2 CNT CCD
Na+ transporters
NCC [30, 31, 66] +++ ++
ENaC [31] + ++ +++
γ-Na+/K+ ATPase [2, 41] +++ + + +
Mg2+ transporters
TRPM6 [66] +++ ++
Ca2+ transporters
TRPV5 [30] +++ ++
Calbindin-D28K [30, 31] + +++ ++ ++
Parvalbumin [30, 31, 66] + +++
NCX1/PMCA1b [30, 31] + +++ ++
Protein abundance: + weak, ++ intermediate, +++ strong
DCT distal convoluted tubule, DCT1 early DCT, DCT2 late DCT, CNT connecting tubule, CCD cortical collecting duct, NCC thiazide-sensitive
NaCl cotransporter, ENaC the amiloride-sensitive epithelial Na+ channel, TRPV5 transient receptor potential vanilloid 5, TRPM6 transient
receptor potential melastatin 6, NCX1 Na+ /Ca2+ exchanger, PMCA1b Ca2+ -ATPase
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Parvalbumin is strongly expressed in DCT1 and only weakly
in TAL and DCT2 [30, 31, 66]. Given that parvalbumin
co-localizes with TRPM6 in DCT1, it could imply that
parvalbumin may function as a Mg2+-binding protein.
Furthermore, the abundance of CaBP28 is low in DCT1
but high in DCT2, suggesting a minor role for CaBP28 in
Mg2+ reabsorption in DCT. Furthermore, Ca2+ transport
proteins are confined to the DCT2 and CNT. Here, the
epithelial Ca2+ channel TRPV5 is detected, and its expres-
sion pattern changes from prominent apical location in
DCT2 to a progressively weaker apical to cytoplasmic
location in CNT [30]. This suggests that DCT2 is the major
site for transcellular Ca2+ reabsorption. CaBP28 primarily co-
localizes with TRPV5 in DCT2, suggesting a critical role in
transcellular Ca2+ reabsorption. On the basolateral side of
DCT and CNT, the Na+/Ca2+ exchanger (NCX) and Ca2+-
ATPase (PMCA1b) can be found. Both proteins have their
highest abundance in DCT2 and CNT and a weaker
expression in DCT1 [30, 31]. Thus, DCT contains all the
ion transporters to facilitate the transcellular movement of
cations, where DCT1 is critical in fine-tuning Mg2+ and
DCT2 for Ca2+ handling. So far, the process of transcellular
Ca2+ reabsorption has been investigated in great detail [19,
64]. In contrast, research on the molecular mechanism of
transcellular Mg2+ reabsorption in DCT is still at an early
stage. This could in part be due to the lack of specific blockers
of Mg2+ reabsorption or an easy and reliable way to measure
Mg2+ concentrations with fluorescent dyes or isotopes. Thus
far, research on the molecular defect underlying inherited
forms of hypomagnesemia has been instrumental in the
elucidation of transport proteins important in transcellular
Mg2+ reabsorption. This review highlights the recent break-
throughs in this field of research.
DCT is important in transcellular Mg2+ reabsorption
in the kidney
In the nephron, the majority (∼85%) of filtered Mg2+ is
reabsorbed in the proximal tubule and TAL via passive
transport through the tight junctions. DCT reabsorbs ∼10%
of the filtered Mg2+, which is 70–80% of that delivered
from the loop of Henle (Fig. 1) [12]. Using micropuncture
and microperfusion studies of the superficial nephron, it has
been revealed that net Mg2+ reabsorption in DCT is
essentially unidirectional since no secretion of Mg2+ into
the lumen has been reported [12]. Accordingly, this segment
is critical in determining the final urinary excretion. In
general, blood Mg2+ levels are maintained between 0.7 and
1.1 mM [46], and intracellular Mg2+ concentration is
∼0.6 mM being buffered by adenosine triphosphate (ATP)
[12, 62]. The luminal Mg2+ concentration in DCT, however,
is around 0.2–0.7 mM [12], which is lower than the plasma
and intracellular Mg2+ concentration. In addition, using
immortalized mouse DCT cells, Dai and coworkers have
demonstrated that the negative membrane potential directly
determines the Mg2+ influx rate. Indeed, depolarization of
the membrane diminished Mg2+ uptake in these cells [10].
This data would be in line with the operation of a voltage-
driven Mg2+ permeable channel to support the entry of Mg2+
across the apical membrane [11]. Not long ago, this
hypothesis was confirmed as being correct. Patients with
hypomagnesemia with secondary hypocalcemia (HSH), a
primary defect in intestinal and renal Mg2+ absorption, were
found to carry mutations in TRPM6 [47, 50, 67]. TRPM6 is
the first epithelial Mg2+-permeable channel predominantly
present in the luminal membrane of epithelial cells in kidney
and intestine [47, 50, 67]. In concert with TRPM6, the apical
Na+ transporter NCC is indirectly involved in the trans-
cellular movement of Mg2+ in DCT [38]. The evidence for
this notion came from a NCC knockout mouse. Inactivation
of the NCC gene resulted in a mouse model resembling
Gitelman’s syndrome [31], a human disease characterized by
mild renal Na+ wasting, hypocalciuria, hypomagnesemia,
and hypokalemic alkalosis. Although it is still unclear how
NCC dysfunction precisely leads to hypomagnesemia, their
study provides further evidence to support the DCT as the
major site for transcellular Mg2+ reabsorption. Following the
Mg2+ influx in DCT cells, intracellular Mg2+ will be trans-
ported to the basolateral domain for extrusion to the blood
compartment. A putative Na+/Mg2+ exchanger and Mg2+-
ATPase have been proposed as candidates for the extrusion
process [12]. So far, the molecular identities of these
basolateral Mg2+ transporters are unknown. Furthermore,
the basolateral membrane also harbors the receptors for
magnesiotropic hormones, such as epidermal growth factor
(EGF) and 17-β-estradiol [14, 15].
Mg2+ influx in DCT through TRPM6
TRPM6 as the gatekeeper of transcellular Mg2+ reabsorption
TRPM6 is the sixth member in the melastatin subfamily of
transient receptor potential (TRP) ion channels. TRPM6
consists of 39 exons spanning 167 kb of genomic sequence
and coding for a protein of 2,022 amino acids [47, 50, 67].
The TRPM6 protein has six transmembrane-spanning
domains, in which the putative pore region is between the
fifth and sixth domains. It also has a long amino (N)-
terminus and a carboxyl (C)-terminus. TRPM6 has an α-
kinase domain in the C-terminus. This kinase domain plays
an important role in regulating TRPM6 activity. Further,
TRPM6 also displays unique electrophysiological proper-
ties. When heterogeneously expressed in HEK293 cells,
TRPM6 constitutes a channel that is characterized by
extremely small inward but large outward currents [66].
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External divalent cations such as Mg2+ and Ca2+ are
permeable to TRPM6 and at the same time block
monovalent cations permeating through the pore of the
channel [66]. TRPM6 displays strong outward rectification,
has a 5-fold higher affinity for Mg2+ than for Ca2+, and is
blocked in a voltage-dependent manner by ruthenium red
[66]. In other Ca2+-selective channels, there is a 10–1,000
lower affinity for Mg2+ than for Ca2+ [18], which further
favors the TRPM6 identity as Mg2+-permeable channel.
The permeation rank order determined from the inward
current amplitude at −80 mV is Ba2+ ≥ Ni2+ > Mg2+ > Ca2+.
Single-channel conductance of homomeric TRPM6 channel
is 84±2 pS [28]. Amino acid residues E1024, I1030, and
D1031 seem important for channel function and account in
the pore region for TRPM6 permeation properties [61]. In
addition, Li et al. provided evidence that E1029 is also
critical in regulating TRPM6 permeability [27]. It is
remarkable that neutralization of the single amino acid
residue, E1024Q, largely eliminates divalent permeation,
converting the divalent selective TRPM6 to a virtually
monovalent selective channel, and at the same time
abolishes external pH sensitivity [27]. However, the Mg2+
selectivity filter of TRPM6 is still unclear. So far, two
candidate regions in TRPM6 have been proposed as Mg2+
selectivity filters, including 1028GEIDVC1033 [61] and
1024EVYAGE1029 [27]. The missense mutations in TRPM6
identified in HSH lead to nonfunctional, mostly truncated,
TRPM6 proteins [50, 67]. Collectively, these studies
identified TRPM6 as a Mg2+-permeable ion channel.
α-Kinase domain is critical in TRPM6 activity
TRPM6 is a channel kinase with an α-kinase domain fused
to its C-terminus. These kinases display little sequence
similarity with conventional protein kinases. Although α-
kinases can predominantly phosphorylate residues present
in α-helices [48], the α-kinase of TRPM6 is able to
autophosphorylate the channel at several autophosphoryla-
tion sites [8]. Additionally, the autophosphorylation of the
Ser/Thr-rich domain in the α-kinase is critical in the
subsequent phosphorylation of protein substrates by pro-
viding access of the catalytic domain to the substrate [8].
The TRPM6 α-kinase domain is also a regulatory site for
TRPM6 channel activity. For instance, deletion of the α-
kinase domain reduces the TRPM6 current [59]. Further-
more, we have identified receptor of activated protein
kinase C 1 (RACK1) as the first TRPM6-associated protein
that inhibits TRPM6 channel activity depending on the
phosphorylation of the threonine residue at position 1851
(T1851) in the α-kinase domain. RACK1 is a scaffold
protein that binds phosphorylated protein kinase C (PKC)
[45], by which RACK1 can bring the activated PKC into
contact with its various substrates. Using the glutathione S-
transferase (GST)-pull down technology, Cao and col-
leagues revealed that RACK1 is one of the associated
proteins of TRPM6. RACK1 co-localizes with TRPM6 and
NCC in DCT cells, suggesting a role for RACK1 in renal
Mg2+ handling. Indeed, overexpressed RACK1 reduces
TRPM6 currents in an α-kinase activity-dependent manner.
Given that T1851 is crucial for the Mg2+-dependent
autophosphorylation of TRPM6 [6] and channel activity,
these data indicate that RACK1 confers, at least in part, the
Mg2+ sensitivity of TRPM6 channel activity. Taken
together, RACK1 is an intracellular TRPM6-associated
protein that mediates TRMP6 channel activity and thus
renal Mg2+ handling through the TRPM6 α-kinase domain.
Besides RACK1, intracellular ATP also regulates
TRPM6 activity via its α-kinase domain [59]. In the
TRPM6 α-kinase region, there is a conserved ATP-binding
pocket [59]. By binding to this ATP-binding pocket, both
Na+-ATP and Mg2+-ATP inhibited TRPM6 currents in a
dose-dependent manner with a comparable IC50 of ∼1.3 mM
[59]. Mutation of the conserved glycine residue in the ATP-
binding pocket prevented the inhibitory effect of ATP on
TRPM6 channel activity [59]. Interestingly, the α-kinase
domain, but not its activity, is essential for ATP-induced
inhibition on TRPM6 [59]. This result supports the critical
role for the α-kinase domain in TRPM6 regulation. In
contrast to ATP, Na+-CTP or Na+-GTP did not affect the
TRPM6 current in transfected HEK293 cells [59], indicating
the unique role of ATP in regulating the channel. However, it
is still unknown to what extent and how ATP can modulate
the transcellular Mg2+ reabsorption in DCT.
Regulation of TRPM6 by magnesiotropic hormones
Hormones primarily controlling the overall Mg2+ balance
are not generally known (Table 2). Recently, EGF has been
identified as a new magnesiotropic hormone regulating
specifically the renal handling of Mg2+ [15, 35]. In a Dutch
family with isolated recessive renal hypomagnesemia
(IRH), Tiel Groenestege and colleagues employed a
homozygosity-based mapping strategy and revealed a
mutation in the pro-EGF gene where the highly conserved
proline in the cytoplasmic 1067PKNP1070 motif has been
substituted by a leucine. This mutation diminishes baso-
lateral release of pro-EGF and seriously hampers the EGF-
dependent activation of the basolateral EGF receptor,
leading to insufficient activation of TRPM6, less Mg2+
influx, and IRH [15]. Accordingly, it has been proposed
that the pro-EGF gene mutation may result in improper
basolateral sorting, leading to an inadequate secretion of the
hormone into the circulation. Logically, the next question
was how EGF activates TRPM6. To answer this question, it
was demonstrated that EGF stimulates the mobility of
subcellular TRPM6 to increase the plasma membrane
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expression of TRPM6 [58]. In detail, using the fluorescence
recovery after photobleaching technology and cell surface
biotinylation experiments, Thébault et al. visualized the
EGF-enhanced TRPM6 trafficking from the cytosol to the
plasma membrane [58]. This process is mediated via a
sarcoma inducing gene (Src) kinase and Ras-related C3
botulinum toxin substrate 1 (Rac1) [58]. In line with this
study, Ikari et al. reported that, in renal epithelial cells, EGF
upregulates the TRPM6 expression by increasing the
phosphorylation of extracellular signal-regulated kinases 1
and 2 (ERK1/2), leading to Mg2+ influx and an increase in
cell proliferation [23]. In agreement with this study, the
blockade of the EGF receptor (EGFR) induces hypomagne-
semia. This is commonly seen in the colorectal cancer patients
undertaking treatment with an EGFR-targeting antibody,
cetuximab, and can now be explained by the inhibition of
TRPM6 through the block of EGFR by cetuximab [15, 57].
Collectively, these data provide an insight into the mecha-
nism of EGFR activation of TRPM6 and reiterate the
importance of EGF in the overall Mg2+ homeostasis.
Another magnesiotropic hormone is 17-β-estradiol as
evidenced by Tiel Groenestege et al., who showed that 17-
β-estradiol upregulates mRNA level of TRPM6 in mouse
kidney [14]. In line with this observation, surgical removal
of ovary in rats caused a significantly reduction of TRPM6
mRNA level in the kidney, indicating the regulatory role of
estrogen in the transcription process of TRPM6. In
addition, subsequent treatment with 17-β-estradiol restored
the TRPM6 mRNA levels [14], further supporting the
candidature of 17-β-estradiol as a magnesiotropic hormone.
In fact, this is also in agreement with a previous clinical
study, showing that estrogen substitution therapy signifi-
cantly decreases postmenopausal hypermagnesuria [32, 49].
Therefore, it is likely that 17-β-estradiol regulates trans-
cellular Mg2+ reabsorption via an enhanced renal TRPM6
expression [14].
Besides EGF and 17-β-estradiol, other hormones includ-
ing calcitonin, glucagon, arginine vasopressin, mineralocorti-
coid hormones, prostaglandins, and insulin [12] have been
indirectly implicated in the process of Mg2+ handling, but
their effect on TRPM6 activity is unknown. It has, however,
been suggested that parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) do not regulate the
transcription of TRPM6 in mouse [14]. This is interesting
since both hormones have been suggested to increase the
Mg2+ reabsorption in DCTs as evidenced from in vivo
microperfusion experiments and immortalized mouse DCT
cells from Mg2+ uptake experiments [12, 42]. Hence, there
must be other pathways for PTH and 1,25(OH)2D3 to
enhance transcellular Mg2+ reabsorption. In general, detailed
molecular studies are needed to further substantiate the
involvement of these latter hormones in transcellular Mg2+
reabsorption.
Other factors that regulate TRPM6
Other conditions can also regulate TRPM6 and thus renal
Mg2+ handling, such as metabolic acidosis and alkalosis,
immunosuppressive drugs, and thiazide diuretics (Table 2).
Nijenhuis et al. reported that renal TRPM6 expression in
kidney is decreased by chronic metabolic acidosis but
increased by chronic metabolic alkalosis [37]. Furthermore,
the immunosuppressive drugs tacrolimus and cyclosporin A
both downregulate TRPM6 [22, 36]. Similarly, chronic
application of thiazide diuretics, mimicking Gitelman’s
syndrome, has been shown to reduce TRPM6 expression
[31, 38]. Collectively, these data support the key role of
TRPM6 in transcellular Mg2+ reabsorption and imply
TRPM6 as a potential target for pharmacological treatment
of various Mg2+-deficient disorders.
TRPM6 as distinct Mg2+ channel
TRPM6 and TRPM7 have an overall amino acid sequence
identity of 52%, which increases to more then 80% in the
Table 2 Regulation of TRPM6 channel activity in DCT
Regulatory Factors TRPM6 Reference
PTH = Transcription [14]
Estrogen ⇑ Transcription [14]
EGF ⇑ Trafficking/channel activity [15, 58]
Aldosterone = Transcription [56]
1,25-(OH)2D3 = Transcription [14]
Low dietary Mg2+ ⇑ transcription [14]
Acidosis ⇓ Transcription [37]
Alkalosis ⇑ Transcription [37]
Extracellular acidic pH ⇑ Channel activity [27]
[Mg2+]e ⇓ Channel activity [66]
[Ca2+]e ⇓ Channel activity [66]
RACK1 ⇓ Channel activity [6]
ATP ⇓ Channel activity [59]
[Mg2+]i ⇓ Channel activity [59, 66]
Tacrolimus ⇓ Transcription [36]
Regulators of Na+ transporters
FXYD2-mutant ? [24]
NCC-knockout ⇓ Transcription [36]
Thiazides ⇓ Transcription [38]
Potential MgBP
Parvalbumin Co-localizes in DCT1 [59, 66]
CaBP28 Co-localizes in DCT2 [59, 66]
Putative basolateral transporter
Na+/Mg2+ exchanger ? [12]
Mg2+-ATPase ? [12]
[Mg2+ ]e, extracellular Mg
2+ concentration, [Mg2+ ]i, intracellular Mg
2+
concentration, [Ca2+ ]e extracellular Ca
2+ concentration.
? not known, = no effect, ⇑ transcription upregulation or increase of
channel activity, ⇓ downregulation of transcription or inhibition of the
channel activity
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region between the fifth and sixth transmembrane domains
where the pore-forming loop is presumably located [66].
Moreover, both TRPM6 and TRPM7 have a C-terminal
region with sequence similarities to the atypical α-kinase
family. It is likely that TRPM6 and TRPM7 form distinct
cation channels, but there is also experimental evidence that
they can function as a heteromeric complex (TRPM6/7) [7,
28]. Importantly, there are several signature features of
TRPM6 that distinguish this channel from homomeric
TRPM7 and heteromeric TRPM6/7 channels. TRPM6
single-channel current is larger than TRPM7 or TRPM6/
TRPM7 [28]. At micromolar concentrations, 2-aminoethox-
ydiphenyl borate (2-APB) enhanced TRPM6 but inhibited
TRPM7 currents, whereas at millimolar concentrations, 2-
APB increased TRPM7 and TRPM6/7 currents [28].
Hence, TRPM6 has different pharmacological properties
from TRPM7 and TRPM6/7. Furthermore, the pH sensitiv-
ity of TRPM6 is distinctive from those of TRPM7 channels
and TRPM6/7 complexes [28].
Mg2+-binding proteins
Several substances present in DCT cells have the potential
to bind significant amounts of Mg2+, and thus could affect
intracellular free Mg2+ levels. For instance, ATP, CaBP28,
and parvalbumin are abundantly present in DCT [17, 66].
Furthermore, intracellular Mg2+ can also be modulated by
the unidirectional transport of Mg2+ into subcellular
organelles including nucleus, mitochondrion, endoplasmic
reticulum, and ribosomes [17]. At present, evidence for a
Mg2+-binding protein specifically controlling the process of
transcellular Mg2+ reabsorption is lacking. This is in
contrast to transcellular Ca2+ transport, where calbindins
(CaBP28 in kidney and CaBP9 in intestine) specifically
buffer Ca2+ to maintain low intracellular Ca2+ levels during
the process of transcellular Ca2+ (re)absorption, which is a
prerequisite for the signaling function of Ca2+. Additional-
ly, the apical Ca2+ channel TRPV5 is strongly inhibited by
intracellular Ca2+ in the submicromolar range [39]. Hence,
without sufficient local Ca2+-buffering, the Ca2+ influx via
TRPV5 would not be feasible. In contrast, extracellular and
intracellular Mg2+ levels are both in the submillimolar
range. Thus, there is virtually no chemical gradient of Mg2+
across the plasma membrane, and this questions the necessity
of a specific Mg2+-binding protein. However, Voets and
coworkers reported that the activity of TRPM6 is strongly
controlled by the local Mg2+ concentrations with an IC50 of
0.5 mM, suggesting that adequate Mg2+ buffering could be
important. Indeed, both parvalbumin and CaBP28 partly co-
localize with TRPM6 in the DCT and could thus potentially
function as local Mg2+ buffers. A recent study using
parvalbumin knockout mouse failed to show a disturbance
in the Mg2+ homeostasis, which seriously questions the
candidateship of parvalbumin [4]. However, this may be due
to a compensatory intestinal Mg2+ hyperabsorption, or
increased high bone turnover could occur in these knockout
mice. Similarly, this compensatory situation also happens in
the CaBP28−/− mouse, which does not exhibit hypocalcemia
[13]. Alternatively, ATP could, in addition to its direct effect
on TRPM6 activity, also function as physiological and local
Mg2+ buffer [59]. Taken together, further experimental
studies are needed to fully understand the role of Mg2+-
binding substances in transcellular Mg2+ reabsorption.
Mg2+ extrusion systems
A Na+/Mg2+ exchanger and a Mg2+ pump, in analogy with
Ca2+ extrusion systems, have been postulated as candidates
for Mg2+ extrusion system [12]. A putative Na+/Mg2+
exchanger has been studied functionally in many cells
including epithelial cells, but its molecular identity remains
unknown [16, 26, 52]. Schweigel and colleagues showed
that sheep rumen epithelial cells take up Mg2+ when
incubated in a Mg2+-containing medium and that this uptake
is stimulated when the external medium contains no or small
amounts (10 mM) of Na+ [52, 53]. Moreover, this Mg2+
influx was accompanied by a decrease in the intracellular
Na+ concentration and reduced by quinidine and imipramine,
which are both putative inhibitors of Na+/Mg2+ exchange
[63]. Collectively, these data suggest the existence of a Na+/
Mg2+ exchanger in epithelial cells, but its presence remains
to be shown in the DCT. Alternatively, a Mg2+ pump, which
molecular identity awaits experimental confirmation, has
been proposed [51]. Taken together, further investigation is
necessary to explore the molecular details of the Mg2+
extrusion across the basolateral membrane of DCT cells.
Diseases related to Mg2+ handling in DCT
Abnormal Mg2+ handling in the DCT, which is the major
site of transcellular Mg2+ reabsorption, can cause sever
hypomagnesemia [60], including HSH [50], isolated dom-
inant hypomagnesemia (IDH) [5, 34], and Gitelman’s
syndrome [31, 38].
TRPM6 mutation leads to HSH
The HSH is an autosomal recessive disease characterized by
hypomagnesemia and hypocalcemia. The latter is possibly
secondary to parathyroid failure resulting from Mg2+ defi-
ciency due to Mg2+ mal(re)absorption [1]. Patients show
neurologic symptoms of hypomagnesemia during infancy,
including seizures and muscle spasms. Oral administration of
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high doses of Mg2+ can relieve clinical symptoms. Without
treatment, it may be fatal or may result in neurological
damage. In 2001, two different groups simultaneously
discovered that HSH is caused by mutations in TRPM6
[50, 67]. This serendipitous discovery demonstrates that
TRPM6 is the epithelial Mg2+ channel primarily controlling
intestinal Mg2+ uptake and renal Mg2+ excretion.
FXYD2 mutant induces IDH
The FXYD2 gene encodes a single transmembrane protein
that functions as the γ-subunit of Na+/K+-ATPase. A
mutation of FXYD2 substituting glycine at position 41 to
arginine (FXYD2-G41R) causes IDH, a dominant renal
hypomagnesemia associated with hypocalciuria through a
dominant negative mechanism [33, 34]. These disorders
share the general symptoms of hypomagnesemia, tetany,
and epileptiformic convulsions and often include secondary
or associated disturbances in Ca2+ excretion. The γ-subunit
is a small hydrophobic protein of 10 kDa, originally
identified in purified preparations of the Na+/K+-ATPase.
FXYD2 protein is highly expressed in the basolateral
membrane of TAL and DCT [2, 41]. In kidneys of FXYD2
knockout mouse, Na+/K+-ATPase displayed a higher
apparent affinity for Na+ without significant change in
apparent affinity for K+ compared to wild-type animals
[24]. The consequence of this alteration in affinity for the
Mg2+ flux across the DCT is, despite intense research, not
yet elucidated. Surprisingly, these knockout mice apparent-
ly do not exhibit a disturbance in overall Mg2+ balance as
reflected by normal blood and urine Mg2+ values [24],
indicating that the presence of wild-type FXYD2 per se is
not required for the maintenance of the Mg2+ balance. Since
a mutation (G41R) in, unlike a knockout of, FXYD2 causes
renal Mg2+ wasting and consequently hypomagnesemia, the
mutant protein possibly impairs another protein partner
directly regulating the Mg2+ handling in DCT [34]. Now,
the exact molecular consequence of FXYD2-G41R remains
elusive. Indeed, it may cause malfunctioning of the Na+/K+-
ATPase by destabilizing the association between FXYD2
and Na+/K+-ATPase [5] and thus directly depolarize the
membrane potential [34]. Alternatively, both wild-type
FXYD2 and FXYD2-G41R mutant form homomeric and
heteromeric oligomers [5]. In Madin–Darby Canine Kidney
(MDCK) cells, wild-type FXYD2 leads to an increase in
transepithelial current, and this current is significantly
reduced by co-transfection with the FXYD2-G41R mutant
[54]. Hence, FXYD2-G41R mutant is dominant over wild-
type FXYD2 [54]. In line with this observation, FXYD2-
G41R has been shown to reduce the trafficking of wild-type
FXYD2 to the plasma membrane [5]. Given that the
dominant nature of the FXYD2-G41R mutation may be
mediated through its association with wild-type FXYD2
[54], the oligomers of FXYD2-G41R mutant with FXYD2
wild-type seems essential for the occurrence of hypomag-
nesemia. Hypothetically, this small protein may directly
regulate the activity of a relevant ion channel, including
TRPM6, as FXYD proteins have in general been consid-
ered as regulators of ion channels [9].
NCC mutations cause Gitelman’s syndrome
Gitelman’s syndrome is one of the most frequently
inherited renal tubular disorders [25]. It is an autosomal
recessive Na+ wasting disease, characterized by hypomag-
nesemia, hypocalciuria, and secondary aldosteronism [25].
This leads to hypokalemia and metabolic alkalosis. Genetic
analysis revealed that this syndrome is caused by mutations
in NCC [55], which has been further confirmed by studies
with NCC knockout mice and the chronic application of
thiazide diuretics [31, 38]. It is still unclear how abolish-
ment of NCC function induces hypomagnesemia. Nijenhuis
et al. have shown that TRPM6 mRNA and protein
abundance are reduced in a mouse model of Gitelman’s
syndrome [38]. Furthermore, the hypomagnesemia in this
mouse model is due to renal Mg2+ wasting [38]. Thus,
reduced NCC activity seems to regulate transcellular Mg2+
reabsorption in DCT by controlling the expression of
TRPM6. In addition, another study has revealed that
aldosterone levels were significantly elevated in NCC
knockout mice compared with wild-type mice [43]. Hypo-
magnesemia has been observed in primary aldosteronism
[68]. Collectively, these data imply that aldosterone may be
involved in hypomagnesemia in Gitelman’s syndrome.
However, surprisingly, a recent report shows that aldosterone
did not affect the TRPM6 expression in mouse kidney [56].
Thus, the molecular mechanism of TRPM6 downregulation
and accompanied hypomagnesemia in Gitelman’s syndrome
is still unclear.
Unresolved issues
The identification of TRPM6 as gatekeeper of transcellular
Mg2+ reabsorption and of EGF and estrogen as magnesio-
tropic hormones acting on TRPM6 are recent break-
throughs in unraveling the molecular mechanism of
transcellular Mg2+ reabsorption in DCT. Our picture of this
process is, however, far from complete, and there are still
many important questions unanswered. The activity of
TRPM6 has been measured in heterogeneous expression
systems like HEK293 cells. Here, the inward Mg2+ current
is surprisingly small at physiological membrane potentials,
and it is unknown how these small inward currents
contribute to the overall transcellular Mg2+ reabsorption
[66]. Furthermore, the contribution of organelles to the
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regulation of intracellular Mg2+ levels is unknown. Given
that Mg2+ with an IC50 of 0.5 mM inhibits TRPM6 activity,
it is important to delineate the role of subcellular organelles,
like nucleus, mitochondria, and endoplasmic reticulum
[44], in this process. Additionally, it is still unspecified
how epithelial cells sense the extracellular Mg2+ concen-
tration in order to trigger Mg2+ reabsorption. It has been
established that the Ca2+-sensing receptor (CaSR) can also
monitor extracellular Mg2+ concentration [20]. Additionally,
CaSR activation may decrease protein kinase A activity,
resulting in a decrease in phosphorylated claudin-16, the
translocation of claudin-16 to lysosome, and a decrease in
paracellular Mg2+ reabsorption [21]. Recently, our group
discovered that CaSR is expressed in basolateral domain in
the DCT cells (unpublished data) and regulates TRPV5
channel activity. Therefore, it would be interesting to test if
this CaSR can sense extracellular Mg2+ concentration and
modulate transcellular Mg2+ reabsorption. Finally, the
relation between Ca2+ and Mg2+ reabsorption in the DCT
needs further investigation. Hypomagnesemia is frequently
accompanied by inappropriate renal Ca2+ wasting, but the
molecular explanation of this phenomenon remains ob-
scure. A multidisciplinary approach to explore disturban-
ces in Mg2+ homeostasis will be necessary to further
increase our understanding of transcellular Mg2+ reab-
sorption and ultimately develop new possibilities to treat
Mg2+-related syndromes.
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